bpc-157 effects on mitochondria Regeneration or Risk? A Narrative Review of for Musculoskeletal Healing From BPC-157 to TB-500 to

The compounds discussed are investigational and, unless otherwise noted, have not been approved for human therapeutic use by Health Canada or any other regulatory body

, -

A., Brigham, L

Who to refer: Patients: with symptoms suggestive of either a spinal cord lesion (subacute combined degeneration or peripheral neuropathy) or visual (optic neuropathy) same day emergency admission not responding haematologically to B12 replacement therapy (where folate and iron stores have been checked and are normal) with suspected malabsorption or disease of the terminal ileum should be referred to Gastroenterology with neurological symptoms should be discussed with Neurology if advice required